Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance
Cancer Cell · 2023-02 · 41 (2) · 272-287.e9
DOI: 10.1016/j.ccell.2023.01.001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Cell, 2023-02. Verfasst von Xiaowei Liu und 15 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University …. Hauptthemen laut MEDLINE: HLA Antigens, Neoplastic Cells, Circulating. Die Arbeit wurde bisher 368-mal zitiert (Crossref) und nennt 61 Literaturangaben. Gefördert von: Shaoxing Bureau of Science and Technology, National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Circulating tumor cells (CTCs), shed by primary malignancies, function as "seeds" for distant metastasis. However, it is still largely unknown how CTCs escape immune surveillance. Here, we characterize the transcriptomes of human pancreatic ductal adenocarcinoma CTCs, primary, and metastatic lesions at single-cell scale. Cell-interaction analysis and functional studies in vitro and in vivo reveal that CTCs and natural killer (NK) cells interact via the immune checkpoint molecule pair HLA-E:CD94-NKG2A. Disruption of this interaction by blockade of NKG2A or knockdown of HLA-E expression enhances NK-mediated tumor cell killing in vitro and prevents tumor metastasis in vivo. Mechanistic studies indicate that platelet-derived RGS18 promotes the expression of HLA-E through AKT-GSK3β-CREB signaling, and overexpression of RGS18 facilitates pancreatic tumor hepatic metastasis. In conclusion, platelet-derived RGS18 protects CTCs from NK-mediated immune surveillance by engaging the immune checkpoint HLA-E:CD94-NKG2A. Interruption of the suppressive signaling prevents tumor metastasis in vivo by immune elimination of CTCs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Integrative Medicine, Clinical Research Center for Breast, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University and Collaborative Innovation Center, Chengdu, Sichuan 610041, China.
- Department of Pancreatic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, China.
- Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China.
- Institutes of Biological Sciences, Zhongshan-Xuhui Hospital, Fudan University, Shanghai 200032, China.
- College of Pharmacy and Biological Engineering, Chengdu University, Chengdu, Sichuan 610106, China.
- Department of Biotherapy, West China Hospital and State Key Laboratory of Biotherapy, Sichuan University, Chengdu, Sichuan 610041, China. Electronic address: drmaxuelei@gmail.com.
Förderung
- Shaoxing Bureau of Science and Technology
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Sichuan University
- China Postdoctoral Science Foundation
Zitieren
APA
Liu, X., Song, J., Zhang, H., Liu, X., Zuo, F., Zhao, Y., Zhao, Y., Yin, X., Guo, X., Wu, X., Zhang, H., Xu, J., Hu, J., Jing, J., Ma, X., & Shi, H. (2023). Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell, 41(2), 272-287.e9. https://doi.org/10.1016/j.ccell.2023.01.001
Vancouver
Liu X, Song J, Zhang H, Liu X, Zuo F, Zhao Y, et al. Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance. Cancer Cell. 2023;41(2):272-287.e9. doi:10.1016/j.ccell.2023.01.001
BibTeX
@article{Liu2023,
author = {Liu, Xiaowei and Song, Jinen and Zhang, Hao and Liu, Xinyu and Zuo, Fengli and Zhao, Yunuo and Zhao, Yujie and Yin, Xiaomeng and Guo, Xinyu and Wu, Xi and Zhang, Hu and Xu, Jie and Hu, Jianping and Jing, Jing and Ma, Xuelei and Shi, Hubing},
title = {Immune checkpoint HLA-E:CD94-NKG2A mediates evasion of circulating tumor cells from NK cell surveillance},
journal = {Cancer Cell},
year = {2023},
volume = {41},
number = {2},
pages = {272--287.e9},
doi = {10.1016/j.ccell.2023.01.001}
}
EUVIMED